BenevolentAI Investor Conference Presentation Deck
H1 2023 Financial highlights
Revenue
Research and development¹
G&A - Business operations ["Bus Ops"]¹
G&A - Unrealised foreign exchange (loss)/gain
Normalised share-based payment ("SBP") expenses
Other income
Normalised operating loss
Normalised EPS (in pence)²
Weighted average ordinary shares outstanding (in millions)
1. Excludes exceptional costs related to the restructuring programme and Business
Combination, in addition to SBP expenses and unrealised FX losses/gains.
2. Normalised EPS also excludes taxation impact from exceptional items and finance
income related to the Business Combination.
Six months ended
30 June
2023
£'000
5,297
(31,506)
(11,451)
(409)
(2,600)
109
(40,560)
(27.0)
117.5
BenevolentAl Proprietary
2022
£'000
4,843
(29,976)
(9,730)
3,221
(19,869)
72
(51,439)
(45.2)
100.5
Revenue increase across AstraZeneca
collaboration, reflecting the ongoing
second Al-enabled drug discovery
collaboration with AstraZeneca.
R & D spend increase driven by
advancing pipeline into later stages of
development, in particular BEN-8744
and its preparation for the P1 trial in H2
2023, combined with an increase in
staff-related costs supporting the
continued innovation of the
Benevolent Platform™.
The Group also has costs relate to
BEN-2293 which, as communicated in
May 2023, will not be subject to further
investment following the Phase 2a trial
results.
Bus Ops spend has increased driven
by a full six months of listing costs in
H1 2023, as compared to 2 full months
in H1 2022.
Benevolent 20View entire presentation